Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118542 | 0.86 | CYP2C19 (0.57) | MAPK1CYP2C19POLBCYP1A2NPC1 | |
| SCHEMBL6421670 | 0.86 | CYP2C19 (0.61) | MAPK1CYP2C19POLBCYP1A2NPC1 | |
| SCHEMBL30040195 | 0.86 | CYP2C19 (0.61) | MAPK1CYP2C19POLBCYP1A2NPC1 | |
| SCHEMBL11063278 | 0.85 | CYP2C19 (0.60) | MAPK1CYP2C19POLBCYP1A2NPC1 | |
| SCHEMBL17359620 | 0.82 | ELANE (0.47) | MAPK1SMN1; SMN2ALDH1A1TSHRHPGD | |
| SCHEMBL15696574 | 0.82 | CYP2C19 (0.53) | MAPK1CYP2C19POLBCYP1A2NPC1 | |
| SCHEMBL31520104 | 0.82 | MAPT (0.55) | MAPK1CYP2C19POLBCYP1A2ALDH1A1 | |
| SCHEMBL8752477 | 0.81 | CYP2C19 (0.59) | MAPK1CYP2C19POLBCYP1A2NPC1 | |
| SCHEMBL980175 | 0.81 | CYP2C19 (0.59) | MAPK1CYP2C19POLBCYP1A2NPC1 | |
| SCHEMBL8752502 | 0.79 | KDM4E (0.60) | MAPK1CYP2C19POLBCYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137314-A1 | HARMFUL ORGANISM CONTROL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100099692-A1 | HARMFUL ORGANISM CONTROL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| WO-2004087637-A1 | PRODUCTION OF N-ALKYLAMIDE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-10-14 | — | — | WO | disclosed |
| CN-1014060-B | METHOD FOR PREPARAING ORTHO-AZONAPHTHALENE COMPOUND | IMP CHEMICAL IND PAN AMERICAL (US) | 1991-09-25 | — | — | CN | disclosed |
| EP-0205272-B1 | CINNOLINE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-08-14 | — | — | EP | disclosed |
| US-4886800-A | Substituted cinnoline derivatives as CNS depressants | ICI AMERICAS INC. (US) | 1989-12-12 | — | — | US | disclosed |
| CN-86104358-A | The preparation method of cinnoline compound | — | 1987-04-01 | — | — | CN | disclosed |
| EP-0205272-A2 | Cinnoline derivatives | ICI AMERICAS INC. (US) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099692-A1 | HARMFUL ORGANISM CONTROL COMPOSITION | UQCRC1, UQCRC2, Q6ZSR9 | MAPK1 3128/4885CYP2C19 448/4885POLB 364/4885 |
| US-20100137314-A1 | HARMFUL ORGANISM CONTROL COMPOSITION | UQCRC2, UQCRC1, UQCRB | MAPK1 3062/4885CYP2C19 302/4885POLB 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.